← Leaderboards
David Mark Moquin
Massachusetts General Hospital
$173,186
Attributed
$173,186
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $61K · FY2015–17$100K$75K$50K$25K$0
'15
'16
'17
Funding mix
By agency
NIH$173,186 · 1
By mechanism
F32$173,186 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Hensin Tsao$3,663,046
- Bin Deng$2,173,449
- David E Fisher$28,420,496
- Stephen Michael Rothenberg$683,997
- Geoffrey Liu$2,167,420
Others in their field
Top investigators on “Erbb2 Gene”
- Norman Wolmark · Nsabp Foundation, Inc.$43,988,954
- Charles M Perou · Univ Of North Carolina Chapel Hill$10,910,346
- Ellen M Velie · Michigan State University$10,395,017
- Leslie Bernstein · University Of Southern California$10,393,428
- Lewis A Chodosh · University Of Pennsylvania$10,338,684
- Carlos L Arteaga · Vanderbilt University$9,797,101
Research focus
Erbb2 GeneDna RepairDna LesionDna Replication ForkBinding ProteinsBaseBreast Cancer CellAtp PhosphohydrolaseBreast Cancer TreatmentBreast Epithelial CellsBypassCancer CellCancer GenomicsBiochemicalCell ProliferationCellsCell SurvivalChromosomal BreaksCleaved CellDatabasesDissociationDna BiosynthesisDna DamageFamily
Grant awards (3)
Unveiling the mechanism for Spartan-mediated DNA lesion bypass and the implications for breast cancer treatment$60,990
F32 · FY2017 · CA · contact PI
Unveiling the mechanism for Spartan-mediated DNA lesion bypass and the implications for breast cancer treatment$58,002
F32 · FY2016 · CA · contact PI
Unveiling the mechanism for Spartan-mediated DNA lesion bypass and the implications for breast cancer treatment$54,194
F32 · FY2015 · CA · contact PI